Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + abiraterone neoadjuvant study in high-risk localized and oligometastatic prostate cancer
ChiCTR2200060566Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and abiraterone in prostate cancer (PCa), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Pathological complete response and Minimal residual disease. Planned start May 2022; status: not yet recruiting.
02
Drugs
fluzoparibabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2200060566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060566.